Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?
Authors
Keywords
Poly(ADP-ribose) polymerases (PARP), Soft tissue sarcoma (STSs), DNA damage response pathway, Radiation therapy
Journal
Radiologia Medica
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-03-26
DOI
10.1007/s11547-018-0877-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- (Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair
- (2017) Maristella Saponara et al. EUROPEAN JOURNAL OF CANCER
- A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers
- (2017) Kim A. Reiss et al. GYNECOLOGIC ONCOLOGY
- PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
- (2017) Luyao Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
- (2017) Audrey Laroche et al. Journal of Hematology & Oncology
- PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
- (2017) Ymera Pignochino et al. Molecular Cancer
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
- (2017) Paul Lesueur et al. Oncotarget
- Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers
- (2017) Kedar Hastak et al. Oncotarget
- Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
- (2017) Joline Lim et al. Cancers
- Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway
- (2016) Annemiek M. van Maldegem et al. EUROPEAN JOURNAL OF CANCER
- Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor
- (2016) Hiroyuki Yamasaki et al. GENES TO CELLS
- Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells
- (2016) Colin Rae et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality
- (2016) Yanyan Jiang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study
- (2016) Pierre Chabot et al. JOURNAL OF NEURO-ONCOLOGY
- Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
- (2016) Michael McMahon et al. MOLECULAR CANCER RESEARCH
- Knockdown of PARP-1 Inhibits Proliferation and ERK Signals, Increasing Drug Sensitivity in Osteosarcoma U2OS Cells
- (2016) Sheng Li et al. ONCOLOGY RESEARCH
- Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition
- (2016) David A. Gewirtz et al. RADIATION RESEARCH
- SP-0298: Phase I Results of PARPi (Olaparib) + RT + Cetuximab in LAHNSCC
- (2016) D. Raben et al. RADIOTHERAPY AND ONCOLOGY
- EP-2026: Effect of PARP-1 inhibition on human soft tissue sarcoma cells radiosensitivity
- (2016) M. Mangoni et al. RADIOTHERAPY AND ONCOLOGY
- Translational research in diagnosis and management of soft tissue tumours
- (2016) Eugenio Rimondi et al. CANCER IMAGING
- Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
- (2016) Florian Engert et al. Oncotarget
- TBCRC 024 Initial Results: A Multicenter Phase 1 Study of Veliparib Administered Concurrently With Chest Wall and Nodal Radiation Therapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer
- (2015) R. Jagsi et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio
- (2015) Cihan Gani et al. RADIOTHERAPY AND ONCOLOGY
- Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells
- (2015) Caroline V.M. Verhagen et al. RADIOTHERAPY AND ONCOLOGY
- The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
- (2015) José Luis Ordóñez et al. Oncotarget
- Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
- (2015) Sonja J. Gill et al. PLoS One
- Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
- (2014) Edwin Choy et al. BMC CANCER
- Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
- (2014) Britta Vormoor et al. CURRENT OPINION IN ONCOLOGY
- Abstract C206: Pediatric Preclinical Testing Program (PPTP) evaluation of BMN 673, an inhibitor of Poly-ADP Ribose Polymerase (PARP), alone and with Temozolomide (TMZ).
- (2014) M. Smith et al. MOLECULAR CANCER THERAPEUTICS
- An update on PARP inhibitors—moving to the adjuvant setting
- (2014) Amir Sonnenblick et al. Nature Reviews Clinical Oncology
- Targeting the DNA Repair Pathway in Ewing Sarcoma
- (2014) Elizabeth Stewart et al. Cell Reports
- Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair
- (2013) Lauren Shunkwiler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- TDP1 and PARP1 Deficiency Are Cytotoxic to Rhabdomyosarcoma Cells
- (2013) Hok Khim Fam et al. MOLECULAR CANCER RESEARCH
- Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
- (2013) Hae-June Lee et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors
- (2013) Robin E. Norris et al. PEDIATRIC BLOOD & CANCER
- PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
- (2012) J. C. Brenner et al. CANCER RESEARCH
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- 349 Ewing's Sarcoma Cells Can Be Sensitized to Temozolomide and to a Lesser Extent to Radiotherapy by Co-treatment with a PARP-inhibitor (AG014699)
- (2012) B. Vormoor et al. EUROPEAN JOURNAL OF CANCER
- PARP-1 inhibition induces a late increase in the level of reactive oxygen species in cells after ionizing radiation
- (2012) Artur Cieślar-Pobuda et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
- (2011) J. Chad Brenner et al. CANCER CELL
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics
- (2010) Laure Gibault et al. JOURNAL OF PATHOLOGY
- Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance
- (2008) N. Chan et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More